Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739214 | 1.00 | KDM4E (0.53) | KDM4EHPGDALDH1A1TUBB1RAB9A | |
| SCHEMBL17221496 | 0.89 | KDM4E (0.56) | KDM4EHPGDALDH1A1TUBB1RAB9A | |
| SCHEMBL17221495 | 0.89 | KDM4E (0.56) | KDM4EHPGDALDH1A1TUBB1RAB9A | |
| SCHEMBL25337943 | 0.83 | KDM4E (0.50) | KDM4EHPGDALDH1A1RAB9AMEN1 | |
| SCHEMBL25959726 | 0.83 | KDM4E (0.50) | KDM4EHPGDALDH1A1RAB9AMEN1 | |
| SCHEMBL7222223 | 0.79 | HPGD (0.53) | KDM4EHPGDALDH1A1NPC1KMT2A | |
| SCHEMBL1478419 | 0.79 | HPGD (0.53) | KDM4EHPGDALDH1A1NPC1KMT2A | |
| SCHEMBL1478416 | 0.79 | HPGD (0.53) | KDM4EHPGDALDH1A1NPC1KMT2A | |
| SCHEMBL20919118 | 0.77 | MAPT (0.48) | KDM4EHPGDALDH1A1TUBB1RAB9A | |
| SCHEMBL28419553 | 0.77 | MAPT (0.48) | KDM4EHPGDALDH1A1TUBB1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3472161-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| EP-3472161-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221092-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
| US-6680402-B2 | SUCH AS N-PHENYLACETYL-2-DIFLUOROMETHOXY-6-FLUOROBENZAMIDE-O-CYCLOPROPYLMETHYL OXIME | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-20 | — | — | US | disclosed |
| US-20030120085-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | EICKEN KARL (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6509501-B2 | Agriculture | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-21 | — | — | US | disclosed |
| US-20020133025-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | EICKEN KARL (DE) | 2002-09-19 | — | — | US | disclosed |
| US-6420605-B1 | DIFLUOROMETHYL ETHERS OF BENZAMIDOXIME COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133025-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | CBR1, CBR3, CYP1B1 | KDM4E 587/4885HPGD 4355/4885ALDH1A1 316/4885 |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, EED, BMI1 | KDM4E 90/4885HPGD 4474/4885ALDH1A1 550/4885 |
| US-20030120085-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | CBR1, CBR3, CYP1B1 | KDM4E 587/4885HPGD 4355/4885ALDH1A1 316/4885 |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | EZH2, EED, BMI1 | KDM4E 90/4885HPGD 4474/4885ALDH1A1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.